JP2017509690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509690A5 JP2017509690A5 JP2016563909A JP2016563909A JP2017509690A5 JP 2017509690 A5 JP2017509690 A5 JP 2017509690A5 JP 2016563909 A JP2016563909 A JP 2016563909A JP 2016563909 A JP2016563909 A JP 2016563909A JP 2017509690 A5 JP2017509690 A5 JP 2017509690A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- eno1
- subject
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 60
- 101150015836 ENO1 gene Proteins 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 21
- 239000000412 dendrimer Substances 0.000 claims description 18
- 229920000736 dendritic polymer Polymers 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 11
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- 210000003205 muscle Anatomy 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 210000000663 muscle cell Anatomy 0.000 claims description 4
- 230000006362 insulin response pathway Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 208000001280 Prediabetic State Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000002363 skeletal muscle cell Anatomy 0.000 description 4
- 230000002414 glycolytic effect Effects 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 1
- SENLDUJVTGGYIH-UHFFFAOYSA-N n-(2-aminoethyl)-3-[[3-(2-aminoethylamino)-3-oxopropyl]-[2-[bis[3-(2-aminoethylamino)-3-oxopropyl]amino]ethyl]amino]propanamide Chemical group NCCNC(=O)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCC(=O)NCCN SENLDUJVTGGYIH-UHFFFAOYSA-N 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926913P | 2014-01-13 | 2014-01-13 | |
| US61/926,913 | 2014-01-13 | ||
| US201462009783P | 2014-06-09 | 2014-06-09 | |
| US62/009,783 | 2014-06-09 | ||
| US201562100881P | 2015-01-07 | 2015-01-07 | |
| US62/100,881 | 2015-01-07 | ||
| PCT/US2015/011276 WO2015106296A1 (en) | 2014-01-13 | 2015-01-13 | Enolse 1 (eno1) compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509690A JP2017509690A (ja) | 2017-04-06 |
| JP2017509690A5 true JP2017509690A5 (enExample) | 2018-02-22 |
| JP6629234B2 JP6629234B2 (ja) | 2020-01-15 |
Family
ID=53524434
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563908A Expired - Fee Related JP6644006B2 (ja) | 2014-01-13 | 2015-01-13 | エノラーゼ１（ｅｎｏ１）組成物及びその使用 |
| JP2016563909A Expired - Fee Related JP6629234B2 (ja) | 2014-01-13 | 2015-01-13 | エノラーゼ１（ｅｎｏ１）組成物及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563908A Expired - Fee Related JP6644006B2 (ja) | 2014-01-13 | 2015-01-13 | エノラーゼ１（ｅｎｏ１）組成物及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10188708B2 (enExample) |
| EP (2) | EP3094379A4 (enExample) |
| JP (2) | JP6644006B2 (enExample) |
| KR (1) | KR20160106175A (enExample) |
| CN (3) | CN112336851A (enExample) |
| AU (2) | AU2015204451A1 (enExample) |
| BR (1) | BR112016016153A2 (enExample) |
| CA (2) | CA2936691A1 (enExample) |
| EA (1) | EA201691420A1 (enExample) |
| HK (1) | HK1231425A1 (enExample) |
| IL (1) | IL246720A0 (enExample) |
| MX (1) | MX2016009102A (enExample) |
| SG (1) | SG11201605698XA (enExample) |
| WO (2) | WO2015106295A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015204451A1 (en) | 2014-01-13 | 2016-07-28 | Berg Llc | Enolase 1 (Eno1) compositions and uses thereof |
| WO2016210008A1 (en) * | 2015-06-22 | 2016-12-29 | Berg Llc | Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain |
| WO2017062363A1 (en) * | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| EP3465200A4 (en) | 2016-06-05 | 2020-07-08 | Berg LLC | PATIENT STRATIFICATION SYSTEMS AND METHODS AND IDENTIFICATION OF POTENTIAL BIOMARKERS |
| CN107991493B (zh) * | 2017-11-22 | 2020-03-31 | 中国医科大学附属第一医院 | 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用 |
| CN112111462B (zh) * | 2020-09-14 | 2022-08-23 | 兰州大学 | 烯醇化酶eno1单克隆抗体及其应用 |
| US20250243294A1 (en) * | 2021-11-26 | 2025-07-31 | Hunilife Biotechnology, Inc | Methods to regulate glycolysis via targeting extracellular alpha-enolase for treating human diseases |
| CN114533902A (zh) * | 2022-02-28 | 2022-05-27 | 河南师范大学 | 一种过表达lrrc15基因的质粒载体及其制备方法和应用 |
| CN115786317A (zh) * | 2022-12-12 | 2023-03-14 | 江苏三联生物工程股份有限公司 | 重组神经元特异性烯醇化酶及其制备方法与应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69233126T2 (de) | 1992-09-25 | 2004-04-15 | Neorx Corp., Seattle | Therapeutischer inhibitor der vaskulären glatten muskelzellen |
| EP0787147A1 (en) | 1994-10-25 | 1997-08-06 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US20030044795A1 (en) | 1996-09-06 | 2003-03-06 | Inger Byrajalsen | Biochemical markers of the human endometrium |
| US7078375B1 (en) | 1996-10-25 | 2006-07-18 | Peter Mose Larsen | Diabetes-mediating proteins and therapeutic uses thereof |
| US6329501B1 (en) | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
| WO2001016323A2 (en) | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| EP1238072A2 (en) | 1999-09-01 | 2002-09-11 | Subsidiary N0. 3, INC. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| AU2470101A (en) | 1999-10-25 | 2001-05-08 | Affymetrix, Inc. | Genetic sequences associated with neural cell proliferation and disease |
| JP2003522183A (ja) | 2000-02-02 | 2003-07-22 | トランジェーヌ、ソシエテ、アノニム | ターゲッティングペプチド |
| US20030203372A1 (en) | 2000-12-08 | 2003-10-30 | Ward Neil Raymond | Analysis method |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| US20040058326A1 (en) | 2001-07-27 | 2004-03-25 | Brooksbank Robert Alan | Identification and use of molecules implicated in pain |
| US20050191627A1 (en) | 2001-09-28 | 2005-09-01 | Incyte Corporation | Enzymes |
| WO2003064501A1 (en) | 2002-01-31 | 2003-08-07 | Clarke Slemon | Conformationally restricted compounds as dendrimer cores |
| US20050222023A1 (en) | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
| JP2004081111A (ja) | 2002-08-27 | 2004-03-18 | Yamaguchi Technology Licensing Organization Ltd | 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法 |
| AU2003295401B2 (en) | 2002-11-08 | 2010-04-29 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
| CN100469370C (zh) * | 2002-12-06 | 2009-03-18 | 法布罗根股份有限公司 | 一种稳定HIFα的制剂在制备调节脂肪代谢的药物中的应用 |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US20040219572A1 (en) | 2002-12-17 | 2004-11-04 | Jie Chen | Specific markers for pancreatic cancer |
| WO2004061088A2 (en) | 2002-12-30 | 2004-07-22 | Ppd Development, Lp | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO2004084950A2 (en) | 2003-03-24 | 2004-10-07 | Case Western Reserve University | Cell targeting methods and compositions |
| US7473531B1 (en) | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2005073621A (ja) | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | 脳腫瘍マーカーと脳腫瘍の診断方法 |
| CA2540529C (en) | 2003-10-03 | 2012-03-13 | Vib Vzw | Means and methods for the recruitment and identification of stem cells |
| US8133733B2 (en) * | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| EP1664775A4 (en) | 2004-07-06 | 2008-03-12 | Kuhnil Pharm Co Ltd | COMPOSITION FOR THE DIAGNOSIS OF RETINAL VASCULAR DISEASE COMPRISING ALDOLASE AND DIAGNOSTIC METHOD USING THE SAME |
| US20090221505A1 (en) | 2004-11-16 | 2009-09-03 | Mikhail Kolonin | Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display |
| US20080138913A1 (en) * | 2005-01-03 | 2008-06-12 | Sook-Yeong Jeon | Composition for Prevention, Treatment, and Diagnosis of Chronic Inflammatory Airway Diseases |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| PL1877099T3 (pl) | 2005-04-06 | 2013-02-28 | Genzyme Corp | Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą |
| US20070248628A1 (en) | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| TWI304443B (en) | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| EP2121747A2 (en) | 2006-07-27 | 2009-11-25 | Oxford Genome Sciences (UK) Limited | New protein isoforms and uses thereof |
| PL2069395T3 (pl) | 2006-09-29 | 2012-06-29 | Ribovax Biotechnologies Sa | Nowe antygeny i przeciwciała związane z gruczolakorakiem przewodowym trzustki |
| US20100047256A1 (en) | 2007-01-25 | 2010-02-25 | Imperial Innovations Limited | Methods |
| US20090110662A1 (en) | 2007-04-30 | 2009-04-30 | Intezyne Technologies, Inc. | Modification of biological targeting groups for the treatment of cancer |
| EP2167136B1 (en) * | 2007-07-12 | 2016-04-20 | BioMarin Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| JP5429707B2 (ja) | 2008-03-27 | 2014-02-26 | 国立大学法人群馬大学 | 微粒子およびその製造方法 |
| US20110130346A1 (en) | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| EP2315532B1 (en) | 2008-07-18 | 2014-08-20 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating disorders associated with overweight animals |
| EP2194382A1 (en) | 2008-12-03 | 2010-06-09 | Universität des Saarlandes | An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| IT1398782B1 (it) | 2009-09-11 | 2013-03-18 | Novelli | Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi. |
| US20120309684A1 (en) | 2009-11-30 | 2012-12-06 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
| WO2011072290A2 (en) * | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
| MX2012013735A (es) | 2010-05-28 | 2013-04-29 | Mind Nrg Sa | Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos. |
| EP2638058B1 (en) | 2010-11-12 | 2017-01-11 | Merck Sharp & Dohme Corp. | Enolase peptide conjugate vaccines against staphylococcus aureus |
| US20140086895A1 (en) | 2011-05-10 | 2014-03-27 | Universite De Rouen | Methods and pharmaceutical compositions for the treatment of autoimmune diseases |
| GB201113814D0 (en) | 2011-08-10 | 2011-09-28 | Proteome Sciences R & D Gmbh & Co Kg | Materials and methods for determining sensitivity potential of compounds |
| BR112014004902B1 (pt) | 2011-08-30 | 2022-02-08 | United Kingdom Research And Innovation | Peptídeo, composição farmacêutica ou medicamento compreendendo o dito peptídeo e uso do mesmo para tratar distrofia muscular de duchenne |
| JP6820653B2 (ja) | 2011-12-14 | 2021-01-27 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
| EP2877214B1 (en) | 2012-07-26 | 2019-04-24 | Joslin Diabetes Center, Inc. | Predicting diabetic complications |
| CN104780911A (zh) | 2012-10-30 | 2015-07-15 | 粒子科学有限公司 | 具有靶向部分的药物递送粒子制剂 |
| AU2015204451A1 (en) | 2014-01-13 | 2016-07-28 | Berg Llc | Enolase 1 (Eno1) compositions and uses thereof |
| WO2016210008A1 (en) | 2015-06-22 | 2016-12-29 | Berg Llc | Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain |
| WO2017011836A1 (en) | 2015-07-16 | 2017-01-19 | Berg Llc | Enolase 1 (eno1) compositions and uses thereof |
-
2015
- 2015-01-13 AU AU2015204451A patent/AU2015204451A1/en not_active Abandoned
- 2015-01-13 CA CA2936691A patent/CA2936691A1/en not_active Abandoned
- 2015-01-13 AU AU2015204452A patent/AU2015204452A1/en not_active Abandoned
- 2015-01-13 KR KR1020167022300A patent/KR20160106175A/ko not_active Withdrawn
- 2015-01-13 US US14/596,208 patent/US10188708B2/en active Active
- 2015-01-13 EP EP15735142.0A patent/EP3094379A4/en not_active Withdrawn
- 2015-01-13 CN CN202011098097.6A patent/CN112336851A/zh active Pending
- 2015-01-13 WO PCT/US2015/011275 patent/WO2015106295A2/en not_active Ceased
- 2015-01-13 CN CN201580012892.XA patent/CN106659766B/zh active Active
- 2015-01-13 US US14/596,207 patent/US10188707B2/en active Active
- 2015-01-13 EP EP15735001.8A patent/EP3094341B1/en active Active
- 2015-01-13 CN CN201580012874.1A patent/CN106102835B/zh not_active Expired - Fee Related
- 2015-01-13 JP JP2016563908A patent/JP6644006B2/ja not_active Expired - Fee Related
- 2015-01-13 BR BR112016016153A patent/BR112016016153A2/pt not_active Application Discontinuation
- 2015-01-13 EA EA201691420A patent/EA201691420A1/ru unknown
- 2015-01-13 WO PCT/US2015/011276 patent/WO2015106296A1/en not_active Ceased
- 2015-01-13 CA CA2936694A patent/CA2936694A1/en not_active Abandoned
- 2015-01-13 HK HK17105147.2A patent/HK1231425A1/zh unknown
- 2015-01-13 JP JP2016563909A patent/JP6629234B2/ja not_active Expired - Fee Related
- 2015-01-13 MX MX2016009102A patent/MX2016009102A/es unknown
- 2015-01-13 SG SG11201605698XA patent/SG11201605698XA/en unknown
-
2016
- 2016-07-11 IL IL246720A patent/IL246720A0/en unknown
-
2018
- 2018-11-28 US US16/203,016 patent/US20190307864A1/en not_active Abandoned
- 2018-11-28 US US16/202,989 patent/US11224641B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509690A5 (enExample) | ||
| Jain et al. | Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation | |
| JP2019514979A5 (enExample) | ||
| JP2023029942A (ja) | トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療方法 | |
| JP2012530715A5 (enExample) | ||
| ES2968038T3 (es) | Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas | |
| JP2014526441A5 (enExample) | ||
| JP2016511260A5 (enExample) | ||
| Wong et al. | Nanoparticle encapsulated oxytocin increases resistance to induced seizures and restores social behavior in Scn1a-derived epilepsy | |
| US20180161357A1 (en) | Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als) | |
| CN1993137B (zh) | 用于治疗心血管疾病的组合物和方法 | |
| Lamptey et al. | Neurogenic hypertension, the blood–brain barrier, and the potential role of targeted nanotherapeutics | |
| JP2013544245A5 (ja) | ネプリライシンの発現および活性を増大させるための医薬組成物 | |
| US20140148501A1 (en) | Dna aptamers for promoting remyelination | |
| Liu et al. | Targeted delivery of macrophage membrane biomimetic liposomes through intranasal administration for treatment of ischemic stroke | |
| RU2012100778A (ru) | Использование лхат для лечения анемии и дисфункции красных кровяных клеток | |
| US9254312B2 (en) | Method for the treatment and/or prophylaxis of multiple sclerosis, and use of erythropoietin for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple sclerosis | |
| US9856475B2 (en) | Formulations for treating amyloidosis | |
| JP2014504601A5 (enExample) | ||
| EP3212634B1 (en) | Compounds to suppress autoimmune response | |
| CN111201029B (zh) | Zag来源肽及其用途 | |
| US11453880B2 (en) | Chimeric decoy | |
| CN112567037B (zh) | 治疗或诊断tnf相关炎性疾病的tnf靶向适配体及其用途 | |
| CN104853778A (zh) | 用于肌萎缩性侧索硬化的治疗剂 | |
| EP4566614A1 (en) | DRY EYE REMEDY CONTAINING DNA OLIGONUCLEOTIDE SELECTIVELY BINDING TO IFN-y |